ADVANCING HEALTHY COMMUNITIES: SPRING VALLEY RESIDENTS MAKE EFFORTS TO REDUCE CRIME AND HARMS FROM DRUGS AND ALCOHOL, WHILE IMPROVING COMMUNITY HEALTH Printer-friendly version December 2022 Articles ...

Data shows a 39% increase in cannabis use, along with a rise in nyaope use from 6% to 7.4%. Nyaope – also known as pinch, ...

NACADA led national event in Embu to mark the international day against drug abuse, urging Kenyans to invest in prevention to ...

Prithviraj Sukumaran too voiced his support for the anti-drug initiative, telling the younger generation that no great work ...

Every year on June 26th, Rwanda and the world mark the International Day Against Drug Abuse and Illicit Trafficking. This day serves as a strong reminder to stand against the rising threat of drug and ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug Administration. With better compliance expected — instead of daily pills on a ...

In times of humanitarian crisis, people struggling with substance use are often overlooked. But during conflict and displacement, drug and alcohol use can increase—along with the need for proper care ...

The U.S. Food and Drug Administration (FDA) on June 18 approved a newly developed HIV/AIDS prevention drug that only needs to be taken by injection once every six months. The new drug, lenacapavir ...

A Yeztugo vial. Gilead Sciences US: FDA approves powerful HIV prevention drug: What to know about Yeztugo nbcnews.com Health Jun - 20 - 2025 , 15:47 8 minutes read ...

As with many chronic and often deadly diseases, an ounce of prevention can be worth a ton of cure. It's a breakthrough drug for sure for those wanting to avoid HIV AIDS, but the price is eye popping.

Why FDA approval of new HIV prevention drug is a big deal The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.